SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer

Nature

Volumn 510, Issue 7504, 2014, Pages 283-287

  Mazur, Pawel K ^a   Reynoird, Nicolas ^b   Khatri, Purvesh ^a   Jansen, Pascal W T C ^c   Wilkinson, Alex W ^b   Liu, Shichong ^d   Barbash, Olena ^e   Van Aller, Glenn S ^e   Huddleston, Michael ^e   Dhanak, Dashyant ^e,f   Tummino, Peter J ^e   Kruger, Ryan G ^e   Garcia, Benjamin A ^d   Butte, Atul J ^a   Vermeulen, Michiel ^c,g   Sage, Julien ^a   Gozani, Or ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; PEPTIDES AND PROTEINS; PROTEIN MAP3K2; PROTEIN SMYD3; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

CANCER; CATALYSIS; ENZYME ACTIVITY; INHIBITION; METHYLATION; PATHOGENICITY; PROTEIN; SIGNALING; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; LUNG ADENOCARCINOMA; METHYLATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LUNG NEOPLASMS; LYSINE; MAP KINASE KINASE KINASE 2; MAP KINASE KINASE KINASES; METHYLATION; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOGENE PROTEIN P21(RAS); PANCREATIC NEOPLASMS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS A-RAF; SIGNAL TRANSDUCTION;

EID: 84902333080     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13320     Document Type: Article

References (48)

1. Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480-488 (2013).
2. Watanabe, T. et al. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur. J. Cancer 47, 1946-1954 (2011).
3. Gaedcke, J. et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosom. Cancer 49, 1024-1034 (2010).
4. Hamamoto, R. et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nature Cell Biol. 6, 731-740 (2004).
5. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nature Rev. Cancer 11, 761-774 (2011).
6. VanAller, G. S. et al.Smyd3 regulates cancer cellphenotypesand catalyzes histone H4 lysine 5 methylation. Epigenetics 7, 340-343 (2012).
7. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
8. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
9. Zhu, L., Shi, G., Schmidt, C. M., Hruban, R. H. & Konieczny, S. F. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am. J. Pathol. 171, 263-273 (2007).
10. Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302 (2007).
11. Means, A. L. et al. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 132, 3767-3776 (2005).
12. Morris, J. P. t., Cano, D.A., Sekine, S.,Wang, S. C.&Hebrok, M. b-catenin blocks Krasdependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 120, 508-520 (2010).
13. Bardeesy, N. et al. Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinomain the mouse. Proc. Natl Acad. Sci. USA 103, 5947-5952 (2006).
14. Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572-575 (2010).
15. Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567-571 (2010).
16. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001).
17. Levy, D. et al. A proteomic approach for the identification of novel lysine methyltransferase substrates. Epigenetics Chromatin 4, 19 (2011).
18. Maruyama, T. et al. CHIP-dependent termination of MEKK2 regulates temporal ERK activation required for proper hyperosmotic response. EMBO J. 29, 2501-2514 (2010).
19. Sun, W. et al. MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src. Mol. Cell. Biol. 23, 2298-2308 (2003).
20. Fanger, G. R., Johnson, N. L.&Johnson, G. L.MEK kinases are regulated by EGFand selectively interact with Rac/Cdc42. EMBO J. 16, 4961-4972 (1997).
21. Choi, M. C. et al. A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program. Mol. Cell 47, 122-132 (2012).
22. Matitau, A. E., Gabor, T. V., Gill, R. M.& Scheid, M. P.MEKK2 kinase association with 14-3-3 protein regulates activation of c-Jun N-terminal kinase. J. Biol. Chem. 288, 28293-28302 (2013).
23. Enomoto, A. et al. Negative regulation of MEKK1/2 signaling by serine-threonine kinase 38 (STK38). Oncogene 27, 1930-1938 (2008).
24. Brunet, A., Pages, G. & Pouyssegur, J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 9, 3379-3387 (1994).
25. Raman, M.,Chen, W.&Cobb, M. H. Differential regulationandproperties ofMAPKs. Oncogene 26, 3100-3112 (2007).
26. Eichhorn, P. J., Creyghton, M. P. & Bernards, R. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 1795, 1-15 (2009).
27. Li, Y. M. & Casida, J. E. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc. Natl Acad. Sci. USA 89, 11867-11870 (1992).
28. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet. 29, 418-425 (2001).
29. Kawaguchi, Y. et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nature Genet. 32, 128-134 (2002).
30. Hruban, R. H. et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res. 66, 95-106 (2006).
31. DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protocols 4, 1064-1072 (2009).
32. Winslow, M. M. et al. Suppression of lung adenocarcinomaprogression by Nkx2-1. Nature 473, 101-104 (2011).
33. Tiscornia, G., Singer, O. & Verma, I. M. Production and purification of lentiviral vectors. Nature Protocols 1, 241-245 (2006).
34. Heid, I. et al. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology 141, 719-730 (2011).
35. Mazur, P. K. et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc.Natl Acad. Sci. USA 107, 13438-13443 (2010).
36. Khatri, P. et al. A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J. Exp.Med. 210, 2205-2221 (2013).
37. Storey, J. D. A direct approach to false discovery rates. J. R. Stat. Soc. Series B 64, 479-498 (2002).
38. Dyer, P. N. et al. Reconstitution of nucleosome core particles from recombinant histones and DNA. Methods Enzymol. 375, 23-44 (2003).
39. Brown, M. A., Sims, R. J. III, Gottlieb, P. D. & Tucker, P. W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 5, 26 (2006).
40. Green, E. M., Mas, G., Young, N. L., Garcia, B. A. & Gozani, O. Methylation of H4 lysines 5, 8 and 12 by yeast Set5 calibrates chromatin stress responses. Nature Struct. Mol. Biol. 19, 361-363 (2012).
41. Grey, C. et al. Mouse PRDM9 DNA-binding specificity determines sites of histone H3 lysine 4 trimethylation for initiation of meiotic recombination. PLoS Biol. 9, e1001176 (2011).
42. Kuo, A. J. et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44, 609-620 (2011).
43. Levy, D. et al. Lysine methylation of the NF-kB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kB signaling. Nature Immunol. 12, 29-36 (2011).
44. Moore, K. E. et al. A general molecular affinity strategy for global detection and proteomic analysis of lysine methylation. Mol. Cell 50, 444-456 (2013).
45. Saddic, L. A. et al. Methylation of the retinoblastoma tumor suppressor bySMYD2. J. Biol. Chem. 285, 37733-37740 (2010).
46. Shi, X. et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 27, 636-646 (2007).
47. Strahl, B. D. et al. Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. Mol. Cell. Biol. 22, 1298-1306 (2002).
48. Tachibana, M., Sugimoto, K., Fukushima, T. & Shinkai, Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J. Biol. Chem. 276, 25309-25317 (2001).